57774-35-3

Basic information

• Product Name: 4'-Bromo-4-cyano-biphenyl
• Synonyms: 4'-Bromo-4-cyano-biphenyl;4'-bromo-[1,1'-biphenyl]-4-carbonitrile;4-(4'-Bromophenyl)benzonitrile
• CAS NO: 57774-35-3
• Molecular Formula: C₁₃H₈BrN
• Molecular Weight: 258.11332
• Mol File: 57774-35-3.mol
• Article Data: 5

Chemical Properties

• Melting Point: 144 °C(Solv: ethanol (64-17-5))
• Boiling Point: 120 °C(Press: 1 Torr)
• Appearance: /
• Density: 1.48±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 4'-Bromo-4-cyano-biphenyl(CAS DataBase Reference)
• NIST Chemistry Reference: 4'-Bromo-4-cyano-biphenyl(57774-35-3)
• EPA Substance Registry System: 4'-Bromo-4-cyano-biphenyl(57774-35-3)

Safety Data

• Hazardous Substances Data: 57774-35-3(Hazardous Substances Data)

Usage

General Description

4'-Bromo-4-cyano-biphenyl is a chemical compound with the molecular formula C13H8BrN. It is a derivative of biphenyl, with a bromine atom and a cyano group attached to the benzene rings. It is a white to light yellow solid that is insoluble in water but soluble in organic solvents. 4'-Bromo-4-cyano-biphenyl is mainly used in the synthesis of liquid crystals, which are used in various display technologies such as LCD screens. It can also be used as an intermediate in the production of pharmaceuticals and agrochemicals. Additionally, 4'-bromo-4-cyano-biphenyl has been investigated for its potential use as a catalyst in organic reactions due to its unique electronic and steric properties. However, it should be handled with care as it is considered to be toxic if ingested or inhaled, and it may cause skin and eye irritation upon contact.

Upstream product

• 2863-98-1 4-hydrazinobenzonitrile hydrochloride 
• 622-88-8 4-bromophenylhydrazine hydrochloride 
• 589-87-7 1,4-bromoiodobenzene 
• 126747-14-6 4-cyanophenylboronic acid 

Downstream Products

• 1214278-85-9 1-(tert-butoxycarbonyl)-2-(4'-cyanobiphenyl-4-yl)-1hindole-6-carbonitrile 
• 1214278-84-8 1-(tert-butoxycarbonyl)-2-(4'-cyanobiphenyl-4-yl)-1hindole-5-carbonitrile 
• 1219958-87-8 C₃₂H₂₁NO 
• 2920-38-9 4-cyano-1,1'-biphenyl 
• 130447-14-2 4'''-Dimethylamino-[1,4';1',1'';4'',1''']quaterphenyl-4-carbonitrile 
• 406482-73-3 (4'-cyano-[1,1'-biphenyl]-4-yl)boronic acid 

Relevant articles and documents

Understanding the remarkable difference in liquid crystal behaviour between secondary and tertiary amides: The synthesis and characterisation of new benzanilide-based liquid crystal dimers

A number of liquid crystal dimers have been synthesised and characterised containing secondary or tertiary (N-methyl) benzanilide-based mesogenic groups. The secondary amides all form nematic phases, and we present the first example of an amide to show the twist-bend nematic (NTB) phase. Only two of the correspondingN-methylated dimers formed a nematic phase and with greatly reduced nematic-isotropic transition temperatures. Characterisation using 2D ROESY NMR experiments, DFT geometry optimisation and X-ray diffraction reveal that there is a change in the preferred conformation of the benzanilide core on methylation, fromZtoE. The rotational barrier around the N-C(O) bond has been measured using variable temperature1H NMR spectroscopy. This dramatic change in shape accounts for the remarkable difference in liquid crystalline behaviour between these secondary and tertiary amide-based materials.

Making nonsymmetrical bricks: Synthesis of insoluble dipolar sexiphenyls

A versatile synthesis of nonsymmetrical, terminally substituted p-sexiphenyl (6P) derivatives has been developed. The synthesis makes use of a nonsymmetrical starting material as well as modular functionalization using Suzuki cross-coupling to yield a soluble precursor, which finally is converted to the insoluble target 6P derivatives. These derivatives display similar electronic and optical properties to the parent 6P, yet the permanent dipole along their molecular axis allows for tuning of their self-assembly on various substrate surfaces.

Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use

The present invention is directed to compound of the formula I: STR1 wherein R1, R2, R3, R4, R5, X, Y, and STR2 are as defined herein. These compounds are useful for inhibiting the activity of a metalloproteinase by contacting the metalloproteinase with an effective amount of the inventive compounds.